Strata Critical Medical, Inc. (SRTA) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
Strata Critical Medical, Inc. (SRTA)
A forensic read on Strata Critical Medical, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
6.5
Altman Z-score
Watch
Earnings quality
5
Forensic signals
9.8
P / E (ttm)
17.5%
ROE
$459M
Market cap
Strata Critical Medical, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is 6.5, placing it in the Safe zone. 5 forensic signals were flagged in its latest SEC filings, led by receivables vs revenue.
What the filings flag
74d DSOReceivables vs revenue.Days sales outstanding moved from 49 to 74 days FY2024→FY2025 (receivables +102% vs revenue +34%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections.
-6%Return on invested capital.Return on invested capital is -6% and rising from -16% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+5.1%/yrShare-count dilution.Diluted share count changed +15% over the last 3 years to FY2025 (+5.1%/yr). The count is GROWING — existing holders are being diluted. That's ~5.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~15%.
stoppedShareholder returns — halted.Capital returns have STOPPED — $244,000 of buybacks + dividends in FY2024, but ~$0 in FY2025. A halt usually means the company is conserving cash; understand why before reading it as neutral.
+19.7%Accruals ratio.Net operating assets grew +19.7% relative to their average in FY2025 — the accrual component of earnings. Accruals are building faster than is comfortable — part of profit sits in receivables, inventory or capitalized costs rather than cash. The cash-flow cross-check agrees: reported earnings ran ahead of operating cash by +40% of net operating assets.
Key fundamentals
Net Margin21.0%
Debt / Equity0.00x
Free Cash Flow$-58.5M
Latest Revenue$197.1M
Return on Equity14.8%
Revenue Growth YoY+34.3%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Strata Critical Medical, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about SRTA's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown